22320-10-1

Usage

Uses

Used in Pharmaceutical Industry:
4-Hydroxybenzenebutyric acid methyl ester is used as an intermediate in the synthesis of Arbutamine (A766300) for its role in stimulating adrenergic receptors. This stimulation is essential for the development of cardiac stimulants, which are vital in treating various heart-related conditions.
Used in Cardiac Stimulant Applications:
4-Hydroxybenzenebutyric acid methyl ester is used as a key component in the production of Arbutamine, a cardiac stimulant. Its ability to interact with adrenergic receptors aids in enhancing heart function and providing relief from cardiac issues. This application is particularly important in the development of medications for heart-related conditions, making it a valuable compound in the pharmaceutical sector.

InChI:InChI=1/C11H14O3/c1-14-11(13)4-2-3-9-5-7-10(12)8-6-9/h5-8,12H,2-4H2,1H3

Upstream product

• 67-56-1 methanol 
• 7021-11-6 4-(4-hydroxyphenyl)butanoic acid 
• 20637-08-5 4-(4-methoxyphenyl)butyric acid methyl ester 
• 4521-28-2 4-(4-Methoxyphenyl)butyric acid 
• 74-88-4 methyl iodide 

Downstream Products

• 18093-67-9 4-(p-Isopropyloxy-phenyl)-buttersaeure 
• 18093-69-1 4--buttersaeure 
• 18093-77-1 4-<4-(2.4-Dinitro-phenoxy)-phenyl>-buttersaeure 
• 7021-11-6 4-(4-hydroxyphenyl)butanoic acid 
• 344348-83-0 4-(4-Oxiranylmethoxy-phenyl)-butyric acid methyl ester 
• 425669-66-5 2-methyl-2-{4-[3-(4-methyl-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl)-propyl]-phenoxy}-propionic acid methyl ester 
• 425672-62-4 2-[4-(3-hydrazinocarbonylpropyl)phenoxy]-2-methylpropionic acid tert-butyl ester 
• 425669-58-5 2-methyl-2-{4-[3-(4-methyl-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl)-propyl]-phenoxy}-propionic acid 
• 425669-60-9 2-methyl-2-{4-[3-(5-oxo-4-propyl-4,5-dihydro-1H-[1,2,4]triazol-3-yl)propyl]phenoxy}propionic acid 
• 425672-72-6 2-methyl-2-{4-[3-(5-oxo-4-propyl-4,5-dihydro-1H-[1,2,4]triazol-3-yl)propyl]phenoxy}propionic acid methyl ester 
• 425672-63-5 C₂₀H₃₁N₃O₅ 
• 425674-22-2 2-methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]propyl}phenoxy)propionic acid methyl ester 
• 425672-65-7 4-[2-(1,1-dimethylethoxy)-1,1-dimethyl-2-oxoethoxy]benzenebutanoic acid 2-[(propylamino)carbonyl]hydrazide 
• 425671-29-0 LY 518674 

Relevant academic research and scientific papers

Discovery of novel modulators for the PPARα (peroxisome proliferator activated receptor α): Potential therapies for nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD) is a severe liver disease causing serious liver complications, including nonalcoholic steatohepatitis (NASH). Nuclear receptor PPARα (peroxisome proliferator-activated receptor α) has drawn special attention recently as a potential developmental drug target to treat type-2 diabetes and related diseases due to its unique functions in regulating lipid metabolism, promoting triglyceride oxidation, and suppressing hepatic inflammation, raising interest in PPARα agonists as potential therapies for NAFLD. However, how PPARα coordinates potential treatment of NAFLD and NASH between various metabolic pathways is still obscure. Here, we show that the DY series of novel selective PPARα modulators activate PPARα by up-regulating PPARα target genes directly involved in NAFLD and NASH. The design, synthesis, docking studies, and in vitro and in vivo evaluation of the novel DY series of PPARα agonists are described.

PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS

Disclosed herein, inter alia, are compositions and methods useful for treating liver diseases and metabolic diseases.

G-PROTEIN-CONJUGATED RECEPTOR AGONIST

Disclosed is a novel aralkyl carboxylic acid compound which has an agonistic activity on GPR-120 and/or GPR-40, particularly GPR-120, and is therefore useful as an appetite regulator, an anti-obesity agent, a therapeutic agent for diabetes, a pancreatic beta differentiating cell growth enhancer, a therapeutic agent for metabolic syndrome, a therapeutic agent for a gastrointestinal disease, a therapeutic agent for a neuropathy, a therapeutic agent for a mental disorder, a therapeutic agent for a pulmonary disease, a therapeutic agent for a pituitary hormone secretion disorder or a lipid flavoring/seasoning agent. The aralkyl carboxylic acid compound is represented by the general formula (I). (I) wherein the ring Q represents a pyridyl or the like; R1 represents a C1-6 alkyl group or the like; R2 represents a hydrogen atom, a C1-4 alkyl group or a C1-4 alkoxy group; m and n independently represent an integer of 1 to 5; and X represents an oxygen atom, a sulfur atom or - NR3- [wherein R3 represents a hydrogen atom or a C1-4 alkyl group].

ALKANOIC ACID DERIVATIVES AND THEIR THERAPEUTIC USE AS HDAC INHIBITORS

The invention related to alkanoic acid derivatives of Formula (IIa) and (IIb). These compounds of the invention were found to have activity as HDAC inhibitors.

CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER

The invention provides novel compounds of formula (I), wherein: R1 is a radical derived from one of the known ring systems; R2 is a phenyl radical optionally substituted; Xn represents a birradical selected from the group consisting of: -(CH2)1-4-, (C2-C4)-alkenyl, (C2-C4)alkynyl, -S-(CH2)1-3-#, and -(CH2)1-3-O-#; wherein the symbol # indicates the position at which Xn is attached to R1; Yn is a birradical selected from the group consisting of: -(CH2)2-4-, -S-(CH2)1-3#, and -O-(CH2)1-3-#,; where in the symbol # indicates the position at which Yn is attached to R2; and R3 is a radical selected from the group consisting of: -OR4. The compounds of formula (I) are useful in the treatment of cancer

Synthetic modification of the 2-oxypropionic acid moiety in 2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid (XK469), and consequent antitumor effects. Part 4

The criteria for the activity of 2-{4-[(7-chloro-2-quinoxalinyl)oxy] phenoxy}propionic acid (XK469) and 2-{4-[(7-bromo-2-quinolinyl)oxy]phenoxy} propionic acid (SH80) against transplanted tumors in mice established in previous studies, require a (7-halo-2

Design and Synthesis of a Potent and Selective Triazolone-Based Peroxisome Proliferator-Activated Receptor α Agonist

A new series of hPPARα agonists containing a 2,4-dihydro-3H-1,2,4-triazol-3-one (triazolone) core is described leading to the discovery of 5 (LY518674), a highly potent and selective PPARα agonist.

Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors

Compounds of the formula are useful in treating disease conditions mediated by TNF-α, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

Ultra-Short-Acting β-Adrenergic Receptor Blocking Agents. 2. (Aryloxy)propanolamines Containing Esters on the Aryl Function

Several short-acting β-adrenergic receptor blocking agents have been prepared by incorporating ester functions into the aryl portion of certain (aryloxy)propanolamine systems.In particular, methyl 3-phenyl>propionate hydrochloride (ASL-8052) was found to be a moderately potent, cardioselective compound with a short duration of action when determined in in vivo canine models.